Abecma, Breyanzi, CARVYKTI, Kymriah, Tecartus, Yeskarta
Human-Based CAR T Cell Therapy: Breakthroughs and Challenges
Introduction In the domain of oncology, immunotherapy has emerged as a pioneering methodology, harnessing the body's immune system to combat malignant tumors. There are many immunotherapeutic approaches, but Chimeric Antigen Rece..
Breyanzi, Juno Therapeutics, Large B-cell lymphoma, LBCL, TRANSFORM
Lisocabtagene maraleucel is approved by FDA for second-line treatment of large B-cell lymphoma
July 2022: Lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) has been approved by the Food and Drug Administration for adult patients with large B-cell lymphoma (LBCL) who have refractory disease to first-line chemoi..
BMS, Breyanzi, CAR - T Cell therapy, CAR T-Cell, CART therapy, USFDA
Breyanzi – New CAR T-Cell therapy from BMS
July 2021: Breyanzi (Lisocabtagene maraleucel; liso-cel), a novel CD19-directed chimeric antigen receptor (CAR) T cell treatment developed by Bristol Myers Squibb (BMS), has been approved by the US Food and Drug Administration (US..